Mixed Dyslipidemia Among Patients Using Lipid-Lowering Therapy in French General Practice: An Observational Study

Ganse, Éric Van; Laforest, Laurent; Burke, Thomas; Phatak, Hemant; Souchet, T.

doi:10.1016/j.clinthera.2007.08.003

Cited by 29 publications

(24 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous research has shown that the prevalence of MLD associated with mixed dyslipidemia among patients primarily treated with statins is as high as 30–40% [27,28,29]. Accompanying this observation, these results suggest that the effect of MLD, in addition to elevated LDL-C, on resource utilization among patients primarily treated with statins is substantial.…”

Section: Discussionsupporting

confidence: 59%

The Effects of Isolated versus Multiple Lipid Disorders on Resource Utilization among Metabolic Syndrome Patients with Lipid Abnormalities despite Lipid-Modifying Treatment

Ambegaonkar

Chirovsky

et al. 2010

Cardiology

View full text Add to dashboard Cite

Objective: The aim of this study was to compare resource utilization among metabolic syndrome (MetS) patients with multiple (≧2) lipid disorders (MLD) versus isolated (any 1) lipid disorder (ILD). Methods: Data for MetS patients on lipid-modifying therapy (LMT) were collected from the 2006 Adelphi Metabolic Syndrome Disease Specific Programme^© cross-sectional study of patients from 5 European countries. The presence of MetS and lipid disorders, including elevated low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG), and low high-density lipoprotein (HDL-C), were based on the National Cholesterol Education Program definitions. Analyses compared primary care physician (PCP) and specialist visits over the past 6 months among ILD versus MLD patients. Results: Among 4,836 MetS patients, 2,843 had ≧1 lipid disorders and were on LMT. Controlling for other risk factors, MLD patients had significantly higher physician visits than those with ILD (p = 0.009), but hospitalizations were not significantly different. Patients experiencing all 3 lipid disorders had significantly more endocrinologist visits (p = 0.002) as compared with ILD patients, while patients with elevated LDL-C and abnormal HDL-C and/or TG compared with isolated elevated LDL-C had significantly more PCP (p = 0.001) and cardiologist visits (p < 0.001). Conclusion: Among MetS patients on LMT, presence of MLD resulted in significantly higher PCP and specialist visits compared with ILD.

show abstract

Section: Discussionsupporting

confidence: 59%

The Effects of Isolated versus Multiple Lipid Disorders on Resource Utilization among Metabolic Syndrome Patients with Lipid Abnormalities despite Lipid-Modifying Treatment

Ambegaonkar

Chirovsky

et al. 2010

Cardiology

View full text Add to dashboard Cite

show abstract

“…A study from France [26], where fibrates are more frequently used found that regardless of LDL-C levels 38.7% had MD defined as elevated TGs and/or low HDL-C, which corresponds to 57% in this study. Fibrates have been shown effective in raising HDL-C and lowering TGs [27] and this could explain some of the difference in findings.…”

Section: Discussionmentioning

confidence: 50%

Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA)

et al. 2010

View full text Add to dashboard Cite

BackgroundData on the prevalence of dyslipidemia and attainment of goal/normal lipid levels in a Swedish population are scarce. The objective of this study is to estimate the prevalence of dyslipidemia and attainment of goal/normal lipid levels in patients treated with lipid modifying therapy (LMT).MethodsThis longitudinal retrospective observational study covers time periods before and after treatment. Data were collected from 1994-2007 electronic patient records in public primary healthcare centers in Uppsala County, Sweden. Patients were included if they had been treated with LMT and had at least one lipid abnormality indicating dyslipidemia and if complete lipid profile data were available. Thresholds levels for lipids were defined as per Swedish guidelines.ResultsAmong 5,424 patients included, at baseline, the prevalence of dyslipidemia (≥1 lipid abnormality) was by definition 100%, while this figure was 82% at follow-up. At baseline, 60% had elevated low-density lipoprotein (LDL-C) combined with low high-density lipoprotein (HDL-C) and/or elevated triglycerides (TG s), corresponding figure at follow-up was 36%. Low HDL-C and/or elevated TGs at follow-up remained at 69% for patients with type 2 diabetes mellitus (T2DM), 50% among patients with coronary heart disease (CHD) and 66% among patients with 10 year CHD risk >20%. Of the total sample, 40% attained goal levels of LDL-C and 18% attained goal/normal levels on all three lipid parameters.ConclusionsFocusing therapy on LDL-C reduction allows 40% of patients to achieve LDL-C goal and helps reducing triglyceride levels. Almost 60% of patients experience persistent HDL-C and/or triglyceride abnormality independently of LDL-C levels and could be candidates for additional treatments.

show abstract

“…Results from the EUROASPIRE III survey of medical records from 2,273 patients with CHD from 8 European countries showed that 46% of all patients and 43% of patients on treatment had total cholesterol ≥4.5 mmol/l [16]. Concurrently, results from France, Spain and the UK suggest that two thirds of patients on lipid-lowering therapy still have at least 1 abnormal lipid parameter [17,18,19]. These findings suggest a need for more intensive and comprehensive lipid management among many patients already receiving statin treatment.…”

Section: Introductionmentioning

confidence: 99%

Total Lipid Management and Cardiovascular Disease in the Dyslipidemia International Study

et al. 2013

View full text Add to dashboard Cite

Objectives: Despite statin use, many patients with cardiovascular disease (CVD) are not achieving treatment goals. An international observational study was performed to estimate the prevalence of residual lipid abnormalities in statin-treated patients with CVD to assess whether lipid management requires improvement. Methods: Fasting plasma concentrations of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides were recorded in 11,104 patients with atherosclerotic CVD and ≥3 months of statin therapy. Results: LDL-C and total cholesterol were not at goal levels in 41 and 46% of all patients, respectively; for patients with peripheral artery disease (PAD) only, 59 and 65%, respectively, were not at goal, and in those with coronary heart disease only, 38 and 42%, respectively, were not at goal. Patients with cerebrovascular disease only were least frequently observed to have low HDL-C (24%) and elevated triglycerides (36%). Overall, elevated LDL-C was the most frequent lipid anomaly observed, and preexisting heart failure was strongly and positively associated with dyslipidemia. Conclusions: Approximately two fifths of statin-treated patients with CVD are not reaching lipid goals or have abnormal lipid levels, while patients with PAD could particularly benefit from improved lipid management. In addition to targeting LDL-C, new evidence-based approaches are needed to target low HDL-C and elevated triglycerides.

show abstract

Mixed Dyslipidemia Among Patients Using Lipid-Lowering Therapy in French General Practice: An Observational Study

Cited by 29 publications

References 33 publications

The Effects of Isolated versus Multiple Lipid Disorders on Resource Utilization among Metabolic Syndrome Patients with Lipid Abnormalities despite Lipid-Modifying Treatment

The Effects of Isolated versus Multiple Lipid Disorders on Resource Utilization among Metabolic Syndrome Patients with Lipid Abnormalities despite Lipid-Modifying Treatment

Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA)

Total Lipid Management and Cardiovascular Disease in the Dyslipidemia International Study

Contact Info

Product

Resources

About